Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKahraman, Seda
dc.contributor.authorErul, Enes
dc.contributor.authorSeyyar, Mustafa
dc.contributor.authorGumusay, Ozge
dc.contributor.authorBayram, Ertugrul
dc.contributor.authorOkutur, Sadi Kerem
dc.date.accessioned2023-05-29T12:09:11Z
dc.date.available2023-05-29T12:09:11Z
dc.date.issued2023en_US
dc.identifier.citationKahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A. (2023). Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer. Future Oncology, (0).en_US
dc.identifier.issn1479-6694
dc.identifier.urihttps://doi.org/10.2217/fon-2022-1287
dc.identifier.urihttps://hdl.handle.net/20.500.12294/3874
dc.description.abstractBackground: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.en_US
dc.language.isoengen_US
dc.publisherFUTURE MEDICINE LTDen_US
dc.relation.ispartofFUTURE ONCOLOGYen_US
dc.identifier.doi10.2217/fon-2022-1287en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCDK 4en_US
dc.subject6 Inhibitorsen_US
dc.subjectHER2-Negative Metastatic Breast Canceren_US
dc.subjectHR-Positiveen_US
dc.subjectLetrozoleen_US
dc.titleTreatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast canceren_US
dc.typearticleen_US
dc.departmentTıp Fakültesi, Dahili Tıp Bölümüen_US
dc.authorid0000-0002-8079-7739en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.institutionauthorOkutur, Sadi Kerem
dc.authorwosidFRE-1156-2022en_US
dc.identifier.wosWOS:000991646700001en_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster